Manatuck Hill Partners LLC Makes New Investment in Alpha Cognition, Inc. (NASDAQ:ACOG)

Manatuck Hill Partners LLC purchased a new position in Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 67,000 shares of the company's stock, valued at approximately $395,000. Manatuck Hill Partners LLC owned 0.42% of Alpha Cognition at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Boothbay Fund Management LLC purchased a new position in shares of Alpha Cognition in the fourth quarter worth $1,284,000. Rosalind Advisors Inc. bought a new position in shares of Alpha Cognition during the fourth quarter valued at about $1,489,000. Aristides Capital LLC bought a new position in shares of Alpha Cognition during the fourth quarter valued at about $1,178,000. Altium Capital Management LLC purchased a new stake in shares of Alpha Cognition during the fourth quarter worth about $1,620,000. Finally, National Bank of Canada FI bought a new stake in shares of Alpha Cognition in the fourth quarter worth about $69,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alpha Cognition in a report on Monday, March 31st. Raymond James raised Alpha Cognition to a "moderate buy" rating in a research note on Tuesday, March 25th.

Alpha Cognition Price Performance

ACOG traded up $0.55 on Wednesday, hitting $7.51. The company had a trading volume of 168,629 shares, compared to its average volume of 81,812. The business has a fifty day simple moving average of $5.15. The firm has a market cap of $120.31 million, a price-to-earnings ratio of -2.93 and a beta of 2.48. Alpha Cognition, Inc. has a 52-week low of $3.75 and a 52-week high of $8.61.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.